The condition of the cardiovascular system in patients with relapsing-remitting multiple sclerosis

The aim of the reserch was to study the state of the cardiovascular system, systemic inflammation and balance oxidant/|antioxidant in patients with relapsing-remitting multiple sclerosis.

Material and methods. The study included 45 patients with relapsing-remitting multiple sclerosis (17 men and 28 women), age 28 [24; 32] years, disease duration 5.5 [2; 7] years. The control group included practically healthy patients, age 30 [25; 33] years. Patients with multiple sclerosis were examined neurologically with Expanded Disability Disease Score rating of disability. Instrumental methods included a comprehensive assessment of the cardiovascular system (24-hour Holter ECG monitoring and 24-hour blood pressure monitoring with determination of the daily arterial vascular stiffness, echocardiography). Laboratory methods included clinical and biochemical analysis of blood, lipid profile, glycemia, C-reactive protein. The indices of oxidative stress (acylhydroperoxide) and antioxidant protection (glutathione peroxidase, superoxide dismutase) were studied; a marker of endothelial dysfunction (vascular cellular adhesion molecule-1) were researched.

Results. In the group of patients with multiple sclerosis, there was an increase in C-reactive protein, the marker of endothelial dysfunction compared with the control group (p<0.001). The indicators of oxidative stress and antioxidant protection were statistically significantly increased (p<0.001). According to the results of Daily Blood Pressure Monitoring the variability of systolic blood pressure and diastolic blood pressure during daytime hours was reduced comparison to the control group (р<0,026) and (p<0.002) respectively. The indicators of daily arterial stiffness in the group of patients with multiple sclerosis was statistically significantly increased (p<0.001). According to the results of Holter ECG monitoring, no heart rhythm disorder was detected in both groups. In the group of patients with remitting course of multiple sclerosis, an increase in the number of supraventricular extrasystoles was detected compared with the control group (p<0.005). The main indicators of echocardiography were within normal values, no significant differences between the groups were found.

Conclusion. The study showed that multiple sclerosis patients are at risk of developing cardiovascular diseases and require increased attention to prevent the development.

1. Thompson A.J., Baranzini S.E., Geurts J. et al. Multiple sclerosis. Lancet. 2018; 391 (10130): 1622-1636. doi: 10.1016/S0140-6736(18)30481-1

2. Boiko A., Kesselring J., Paty D.W. et al. Multiple sclerosis and public health. Educational and management implications. World Health Organization, Department of Mental Health, Neuroscience and Neurological Disorders. 1999; 2: 1-11.

3. Gusev E.I., Boiko A.N., Zavalishin I.A. Multiple sclerosis. Clinical Guideline. M.: Real Time. 2011; 43-45, 140-141, 161162. [in Russian].

4. Atlas of MS 2013. URL: http://www.msif.org/wpcontent/uploads/2014/09/Atlas-of-MS.pdf (date of the application: 04.02.2019)

5. Gusev E.I., Boiko A.N., Zavalishin I.A. et all. Epidemiological studies of multiple sclerosis. Methodical recommendation MZ RF № 2003/82. Moscow. 2003; 20-45. [in Russian].

6. Zavalishin I.A. et all. Multiple sclerosis: modern aspects of etiology and pathogenesis. Journal of Neurology and Psychiatry. Special Issue Multiple Sclerosis. 2003; 2: 10-17. [in Russian].

7. Stuifbergen A.K. Physical activity and perceived health status in persons with multiple sclerosis. J Neurosci Nurs. 2007; 29: 238-243. doi: 10.1097/01376517-199708000-00004

8. Warren S.A., Turpin K.V.L., Pohar S.L. et al. Comorbidity and health-related quality of life in people with multiple sclerosis. Int J MS Care. 2009; 11: 6-16. doi: 10.7224/1537-2073-11.1.6

9. Jadidi E., Mohammadi M., Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler. 2013 Sep; 19(10):1336-1340. doi: 10.1177/1352458513475833

10. Marrie R.A., Rudick R., Horwitz R. et al. Vascular comorbidity in associated with more rapid disability progression in multiple sclerosis. Neurology 2010; 74: 1074-1047. doi: 10.1212/WNL.0b013e3181d6b125

11. Murray T.J. The cardiac effects of mitoxantrone: Do the benefits in multiple sclerosis outweigh the risks? Expert Opin Drug Saf. 2006; 5: 265-274. doi: 10.1517/14740338.5.2.265

12. Wei L.., MacDonald TM. and Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004; 141: 764-770. doi: 10.7326/0003-4819-141-10-200411160-00007

13. Kang J.H., Chen Y.H. and Lin H.C. Comorbidities amongst patients with multiple sclerosis: A population-based controlled study. Eur J Neurol. 2010; 17: 1215-1219. doi: 10.1111/j.1468-1331.2010.02971.x

14. Sternberg Z., Leung C., Sternberg D., Li F., Karmon Y., Chadha K., Levy E. The prevalence of the classical and nonclassical cardiovascular risk factors in multiple sclerosis patients. CNS Neurol Disord Drug Targets. 2013; 12: 104-111. doi: 10.2174/1871527311312010016

15. Lutskiy M.A., Esaulenko I.E. Oxidative stress in the pathogenesis of multiple sclerosis. Multiple sclerosis. 2006; 3: 26-30. [in Russian].

16. Marrie R.A., Reider N., Cohen J., Stuve O., Trojano M., Cutter G. et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler. 2015 Mar; 21(3): 263-81. doi: 10.1177/1352458514564491

17. Trifonova S.S., Gaysenok O.V., Sidorenko B.A. Application of methods for assessing the stiffness of the vascular wall in clinical practice: the possibility of cardiovascular index. Cardiology. 2015; (4): 55-61. doi: 10.18565/cardio.2015.4.61-66 [in Russian].

18. Motl R.W., Arnett P.A., Smith M.M. et al. Worsening of symptoms is associated with lower physical activity levels in individuals with multiple sclerosis. Mult Scler. 2008; 14: 140-142. doi: 10.1177/1352458507079126

19. Ohkubo T., Imai Y., Tsuji I. et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama study. Am. J. Hypertens. 2007; (2): 1201-1207. doi: 10.1016/S0895-7061(97)00274-4

20. Witte K., Engelhard S., Janssen B.J. et al. Circadian and short-term regulation of blood pressure and heart rate in transgenic mice with cardiac over expression of the beta1-adrenoreceptor. Chronobiol. Int. 2004; 21(2): 205-216. doi: 10.1081/CBI-120037801

21. Wens I., Dalgas U., Stenager E., Eijnde B.O. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis — a systematic review. Mult Scler. 2013 Oct; 19(12):1556-64. doi: 10.1177/1352458513504252

22. Geraldes R., Esiri M.M., DeLuca G.C., Palace J. Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis. Brain Pathol. 2017; 27(6): 707-722. doi: 10.1111/bpa.12460

23. Jakimovski D., Gandhi S., Paunkoski I., Bergsland N., Hagemeier J., Ramasamy D.P., Hojnacki D., Kolb C., Benedict R.H.B., Weinstock-Guttman B., Zivadinov R. Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. Eur J Neurol. 2019; 26(1): 87-e8. doi: 10.1111/ene.13769

24. Zavalishin I.A., Piradov M.A., Boyko A.N. et all. Autoimmune diseases in neurology. Clinical guideline. M: ROOI «Human Health». 2014; 592 р.

25. Lutskiy M.A. et all. Oxidant stress in the pathogenesis of multiple sclerosis. Journal of neurology and psychiatry named after S.S. Korsakov (Application «Stroke»). 2009: 109:5. 7380. doi: 10.1007/s11055-007-0003-x [in Russian].

26. Spirina N.N., Spirin N.N., Boiko A.N. Effect of alpha-lipoic acid on the severity of endothelial dysfunction in multiple sclerosis. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2018; 8(2): 162. [in Russian].

27. Krotenko N.V., Aliferova V.M., Ivanova S.A. Oxidative stress — a characteristic feature of the pathogenesis of multiple sclerosis. Bulletin of Siberian medicine. 2008; 7(5): 208-214. [in Russian].

28. Spirina N.N., Spirin N.N., Fadeeva O.A. et all. Multiple sclerosis and endothelial dysfunction. 2013; 10 (2): 32-42 [in Russian].